| 항목 | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.54B | $10.60B | $42.88B | $10.36B | $10.86B | $11.12B | $44.56B | $11.01B |
| Net Income | $1.55B | $1.63B | $6.33B | $1.51B | $1.62B | $1.62B | $6.70B | $1.65B |
| EPS (Diluted) | $4.04 | $4.25 | $16.53 | $3.98 | $4.28 | $4.27 | $17.74 | $4.43 |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as ...
🔗 emfls.github.io 다른 콘텐츠 보기
2026년 8월 11일에 재검토했으며 실시간 시세나 투자 권유가 아닙니다. 수익을 보장하지 않고 원금 손실이 가능하므로 공시 원문과 최신 재무자료를 직접 확인하고 필요하면 인가된 전문가와 상담하세요.